Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events

Boehringer Ingelheim and Eli Lilly and Company have announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7000 adults with type 2 diabetes (T2D) at high risk for CV events. EMPA-REG OUTCOME met its primary endpoint and demonstrated superiority of Jardiance, when added to standard of care, in CV risk reduction. The primary endpoint was defined as time to first occurrence of either CV death, or non-fatal myocardial infarction or non-fatal stroke.

Jardiance is the only glucose-lowering agent to have demonstrated CV risk reduction in a dedicated cardiovascular outcomes trial.

"The CV risk reduction Jardiance demonstrated in the EMPA-REG OUTCOME trial is exciting and we look forward to sharing the full results," said Prof. Hans-Juergen Woerle, global vice president medicine, Boehringer Ingelheim. "Approximately 50% of deaths in people with type 2 diabetes worldwide are caused by cardiovascular disease. Reducing cardiovascular risk is an essential component of diabetes management."

The safety profile of Jardiance was consistent with previous studies. Detailed study results will be presented on 17 September at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden.